DeWeirdt, Peter C.
Sanson, Kendall R.
Sangree, Annabel K.
Hegde, Mudra http://orcid.org/0000-0003-4530-4633
Hanna, Ruth E. http://orcid.org/0000-0001-5586-2300
Feeley, Marissa N.
Griffith, Audrey L.
Teng, Teng
Borys, Samantha M. http://orcid.org/0000-0003-4960-131X
Strand, Christine http://orcid.org/0000-0001-5783-6667
Joung, J. Keith http://orcid.org/0000-0001-5630-5645
Kleinstiver, Benjamin P. http://orcid.org/0000-0002-5469-0655
Pan, Xuewen
Huang, Alan
Doench, John G. http://orcid.org/0000-0002-3707-9889
Funding for this research was provided by:
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (5U19AI133524)
Article History
Received: 22 August 2019
Accepted: 9 June 2020
First Online: 13 July 2020
Competing interests
: J.G.D. consults for Foghorn Therapeutics, Maze Therapeutics, Merck, Agios and Pfizer; he also consults for and has equity in Tango Therapeutics. B.P.K. is a scientific advisor to Avectas. T.T., X.P. and A.H. are employees of Tango Therapeutics. J.K.J. has financial interests in Beam Therapeutics, Editas Medicine, Excelsior Genomics, Pairwise Plants, Poseida Therapeutics, Transposagen Biopharmaceuticals and Verve Therapeutics (formerly known as Endcadia); his interests were reviewed and are managed by Massachusetts General Hospital and Partners HealthCare in accordance with their conflict-of-interest policies. He is a member of the Board of Directors of the American Society of Gene and Cell Therapy. J.K.J. and B.P.K. are co-inventors on various patents and patent applications that describe gene editing and epigenetic editing technologies, including the enhanced Cas12a variant used in the present study. A patent application has been filed on the basis of this work.